Close

Natco Pharma unveils generic version of Hepatitis C drug in Nepal

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Syntegon Reports Accelerated Growth in 2024 Results

Syntegon delivers record results in 2024 New strategy fuels...

Agilent Inaugurates India Solution Center to Accelerate Innovation and Expand the Frontiers of Science.

Integrated Facility to Deliver End-to-End, Customized Workflows Across Life...

ACG Packaging Materials Earns SBTi Emission Target Nod

Mumbai, India, May 7, 2025 ACG Packaging Materials, a...

Kindeva bolsters executive team with Chief Quality Officer appointment

A global CDMO and drug delivery expert, has today...

NATCO launches VELPANAT in Nepal- 1st generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination medicine in the country.

Natco Pharma Limited announced that it has launched the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, Inc., under brand name Epclusa®.

Epclusa® is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.

Natco will market Sofosbuvir 400mg/Velpatasvir 100mg under the brand name VELPANAT®. Natco priced its generic medicine of VELPANAT at an MRP of INR 25,000/- equivalent for a bottle of 28 tablets in Nepal. Natco has signed a non-exclusive licensing agreement with Gilead Sciences, Inc., to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.

Latest stories